United Republic of TanzaniaTuberculosis profile
Population  2014 52 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 30 (13–54) 58 (26–104)
Mortality (HIV+TB only) 28 (15–43) 53 (30–84)
Prevalence  (includes HIV+TB) 270 (110–510) 528 (215–979)
Incidence  (includes HIV+TB) 170 (80–290) 327 (155–561)
Incidence (HIV+TB only) 62 (29–110) 120 (56–208)
         
Case detection, all forms (%) 36 (21–77)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.1 (0.5–2) 3.1 (0.9–7.9)
MDR-TB cases among notified pulmonary
TB cases
520 (230–940) 80 (23–200)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 23 583   1 008
Pulmonary, clinically diagnosed 23 380    
Extrapulmonary 13 600    
       
Total new and relapse 61 571    
Previously treated, excluding relapses 1 580    
Total cases notified 63 151    
Among 61 571 new and relapse cases:
6 463 (10%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 9 506 (40%) 882 (34%) 35 923
Laboratory-confirmed RR-/MDR-TB cases     516
Patients started on MDR-TB treatment ***     143
TB/HIV 2014 Number (%)
TB patients with known HIV status 57 612 (91)
HIV-positive TB patients 20 055 (35)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 388 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 16 564 (83)
HIV-positive people screened for TB 525 713  
HIV-positive people provided with IPT 23 124  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (91) 64 053
Previously treated cases, excluding relapse, registered in 2013 (79) 1 679
HIV-positive TB cases, all types, registered in 2013 (72) 20 320
RR-/MDR-TB cases started on second-line treatment in 2012 (73) 45
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 59
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 67
% Funded domestically  
% Funded internationally  
% Unfunded 100%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-29 Data: www.who.int/tb/data